Загрузка...
Tendering and biosimilars: what role for value-added services?
Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and undermine the long-term sustainability of bio...
Сохранить в:
| Опубликовано в: : | J Mark Access Health Policy |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Routledge
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6968494/ https://ncbi.nlm.nih.gov/pubmed/32002174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/20016689.2019.1705120 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|